Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously) and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging its TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Its TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its other drug candidates include IMX-111 and IMX-120. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease.